Tissue mercury levels in humans have increased during the past 50 years to an alarming concentration, with possible deleterious effects that may involve neurological, cardiovascular, and immunological pathology. This article reviews the protocol for the use of oral 2,3-dimercaptopropane-1-sulfonate (DMPS) and oral meso-2, 3-dimercaptosuccinic acid (DMSA) in combination with intravenous glutathione and high-dose vitamin C for treatment of high-level mercury. This protocol yielded an average 69% reduction of urine mercury by provocation analysis.